SB 1631, titled the “Restoring Safeguards for Dangerous Abortion Drugs Act,” would direct the Secretary of Health and Human Services to revoke the current risk evaluation and mitigation strategy (REMS) for mifepristone and replace it with the exact REMS framework that was approved in June 2011. The bill defines mifepristone broadly to include its brand names Mifeprex and Korlym, as well as RU-486, and it would require that a REMS remain in place for the drug, while prohibiting approval of any REMS that differs from the 2011 version.
The bill also creates a federal civil liability framework for harms allegedly caused by abortion drugs. It would allow individuals to sue telehealth providers, pharmacies, or others who knowingly import or transport mifepristone in violation of federal law if the individual suffers bodily injury or mental-health harm attributable, in whole or in part, to use of the drug. Available remedies would include compensatory damages, punitive damages, and attorney’s fees and costs, and the bill states that it does not preempt additional state-law remedies.
In addition, SB 1631 would amend the Federal Food, Drug, and Cosmetic Act to ban importation of mifepristone into the United States, including mailing the drug to individuals. The bill would also make clear that no person may import the drug, and it would add mifepristone to the statute’s import restrictions. If enacted, it would significantly tighten federal controls over access to mifepristone and would likely affect pharmacies, telehealth abortion providers, importers, and patients seeking medication abortion.
The available context shows the bill was introduced and referred to the Senate Committee on Health, Education, Labor, and Pensions, with no recorded votes or committee debate in the provided materials. Based on the bill text and title, the measure appears to be framed by supporters as a safety and regulatory rollback effort, while its practical effect would be to sharply restrict access to medication abortion. Because there are no transcripts or vote records, there is no documented bipartisan or committee-level sentiment in the provided record.
The main point of contention is likely to be abortion policy and federal regulation of mifepristone. Supporters would likely favor restoring older FDA safeguards, banning importation, and creating liability for entities involved in distribution, while opponents would likely view the bill as an attempt to override current FDA policy, restrict telehealth and pharmacy access, and expose providers and intermediaries to litigation. The bill’s explicit preservation of state-law remedies suggests an additional area of legal complexity, but the central dispute is over access to abortion medication and the scope of federal authority over drug safety regulation.
The bill would amend federal drug law, specifically the Federal Food, Drug, and Cosmetic Act, by mandating a specific REMS for mifepristone, prohibiting approval of any different REMS, and banning importation of the drug into the United States. It would also create a new federal private right of action for certain injuries allegedly caused by imported or transported mifepristone, affecting telehealth providers, pharmacies, importers, and others involved in distribution. The measure would not preempt additional state remedies, so it could layer onto existing state tort or consumer-protection laws.
No committee transcript or vote history is provided, so there is no recorded legislative debate or roll-call sentiment in the available materials. From the bill text and title, the measure is clearly framed in strongly restrictive terms toward mifepristone and abortion drugs, suggesting support from abortion opponents and likely opposition from abortion-rights advocates, health-care providers, and telehealth stakeholders. The introduction and referral indicate the bill is at an early stage in the Senate process.
The central controversy is whether Congress should force FDA to restore an older mifepristone REMS and ban importation of the drug. Supporters would likely argue the bill restores safeguards and protects women’s health, while opponents would likely argue it undermines FDA authority, restricts access to medication abortion, and targets telehealth and pharmacy distribution. Another likely point of contention is the bill’s new liability regime, which could expose providers and intermediaries to lawsuits for physical or mental-health harms, even where causation is disputed.